First documented outbreak of KPC-2-producing Klebsiella pneumoniae in Switzerland: infection control measures and clinical management

Infection. 2014 Jun;42(3):529-34. doi: 10.1007/s15010-013-0578-9. Epub 2014 Jan 30.

Abstract

We report the epidemiological and clinical features of the first outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) type 2 in Switzerland. The outbreak took place in the medical intensive care unit (MICU) of our tertiary care hospital and affected three severely ill patients. After the implementation of strict infection control measures, no further patients colonised with KPC-KP could be detected by the screening of exposed patients. Successful treatment of patients infected with KPC-KP consisted of a combination therapy of meropenem, colistin and tigecycline.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Colistin / therapeutic use
  • Disease Outbreaks*
  • Electrophoresis, Gel, Pulsed-Field
  • Genotype
  • Humans
  • Infection Control / methods*
  • Intensive Care Units
  • Klebsiella Infections / epidemiology*
  • Klebsiella Infections / microbiology*
  • Klebsiella Infections / pathology
  • Klebsiella Infections / prevention & control
  • Klebsiella pneumoniae / classification
  • Klebsiella pneumoniae / enzymology
  • Klebsiella pneumoniae / genetics
  • Klebsiella pneumoniae / isolation & purification*
  • Male
  • Meropenem
  • Middle Aged
  • Minocycline / analogs & derivatives
  • Minocycline / therapeutic use
  • Molecular Typing
  • Switzerland / epidemiology
  • Tertiary Care Centers
  • Thienamycins / therapeutic use
  • Tigecycline
  • Treatment Outcome
  • beta-Lactamases / genetics
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Thienamycins
  • Tigecycline
  • beta-Lactamases
  • beta-lactamase KPC-2, Klebsiella pneumoniae
  • Meropenem
  • Minocycline
  • Colistin